Pharmacogenomics of coumarin anticoagulants: are we underestimating the role of CYP2C9?

Thromb Haemost. 2008 Aug;100(2):175-6.

Authors

Tom Schalekamp, Anke-Hilse Maitland-van der Zee, Anthonius de Boer

PMID: 18690332

No abstract available

Publication types

Comment
Editorial

MeSH terms

Anticoagulants / adverse effects*
Aryl Hydrocarbon Hydroxylases / genetics*
Aryl Hydrocarbon Hydroxylases / metabolism
Coumarins / adverse effects*
Cytochrome P-450 CYP2C9
Drug Resistance / genetics*
Hemorrhage / chemically induced
Hemorrhage / genetics*
Humans
Pharmacogenetics
Risk Factors

Substances

Anticoagulants
Coumarins
coumarin
CYP2C9 protein, human
Cytochrome P-450 CYP2C9
Aryl Hydrocarbon Hydroxylases